Deferasirox: Oral, once daily iron chelator - An expert opinion

Indian Journal of Pediatrics

Volumn 77, Issue 2, 2010, Pages 185-191

  Agarwal, M B ^a  

^a BOMBAY HOSPITAL   (India)

Author keywords

Chelation; Deferasirox; Iron; Thalassemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFERRIFERRITHIOCIN;

ABDOMINAL PAIN; ANEMIA; AREA UNDER THE CURVE; ARTHROPATHY; BETA THALASSEMIA; BLACKFAN DIAMOND ANEMIA; CATABOLISM; CHELATION THERAPY; CLINICAL PRACTICE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEART FUNCTION; HEMOSIDEROSIS; HUMAN; IRON BALANCE; IRON BLOOD LEVEL; IRON CHELATION; IRON INTAKE; IRON OVERLOAD; IRON STORAGE; LIVER CELL; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; RECOMMENDED DRUG DOSE; REVIEW; SICKLE CELL ANEMIA; SIDEROSIS; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VOMITING;

BENZOIC ACIDS; CARDIOVASCULAR DISEASES; CHELATING AGENTS; EXPERT TESTIMONY; HEMOSIDEROSIS; HUMANS; IRON; LIVER; THALASSEMIA; TRIAZOLES;

EID: 77749316834     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12098-010-0030-4     Document Type: Review

References (34)

1. J.B. Porter 2001 Practical management of iron overload Br J Haematol 115 239 252 10.1046/j.1365-2141.2001.03195.x 1:CAS:528:DC%2BD3MXptVyru7c%3D 11703317 (Pubitemid 34203484)
2. A. Taher 2005 Iron overload in thalassemia and sickle cell disease Semin Hematol 42 S5 S9 10.1053/j.seminhematol.2005.01.005 1:CAS:528: DC%2BD2MXksFCksbY%3D 15846583 (Pubitemid 40410477)
3. N.F. Olivieri G.M. Brittenham 1997 Iron-chelating therapy and the treatment of thalassemia Blood 89 739 761 1:CAS:528:DyaK2sXptVGntg%3D%3D 9028304
4. K. Thakerngpol S. Fucharoen P. Boonyaphipat 1996 Liver injury due to iron overload in thalassemia: histopathologic and ultrastructural studies Biometals 9 177 183 10.1007/BF00144623 1:CAS:528:DyaK28Xis1elt7Y%3D 8744900
5. N.F. Olivieri 2001 Progression of iron overload in sickle cell disease Semin Hematol 38 57 62 10.1016/S0037-1963(01)90060-5 1:STN:280: DC%2BD3M7ptlWntA%3D%3D 11206962
6. G.J. Kontoghiorghes 2006 Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, Deferoxamine, ICL670, GT56-252, L1NAll and starch Deferoxamine polymers Hemoglobin 30 329 347 10.1080/03630260600642674 1:CAS:528: DC%2BD28XkvFKmsL8%3D 16798657 (Pubitemid 43977334)
7. J.C. Barton 2005 Deferasirox Novartis Curr Opin Investig Drugs 6 327 335 1:CAS:528:DC%2BD2MXjtVOns7Y%3D 15816510
8. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001: 47-61.
9. J.B. Porter 2006 Deferasirox: An effective once-daily orally active iron chelator Drugs Today (Barc) 42 623 637 10.1358/dot.2006.42.10.1009901 1:CAS:528:DC%2BD2sXislKgug%3D%3D (Pubitemid 44901638)
10. H. Nick P. Acklin R. Lattmann 2003 Development of tridentate iron chelators: from desferrithiocin to ICL670 Curr Med Chem 10 1065 1076 10.2174/0929867033457610 1:CAS:528:DC%2BD3sXjs1yjtbo%3D 12678677 (Pubitemid 36582249)
11. J.L. Stumpf 2007 Deferasirox Am J Health Syst Pharm 64 606 616 10.2146/ajhp060405 1:CAS:528:DC%2BD2sXktFOhsbg%3D 17353569 (Pubitemid 46481861)
12. H.E. Vanorden T.M. Hagemann 2006 Deferasirox-an oral agent for chronic iron overload Ann Pharmacother 40 1110 1117 10.1345/aph.1G566 1:CAS:528:DC%2BD28XmsFyqtrY%3D 16735647 (Pubitemid 43886969)
13. H. Glickstein R.B. El M. Shvartsman Z.I. Cabantchik 2005 Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells Blood 106 3242 3250 10.1182/blood-2005-02-0460 1:CAS:528:DC%2BD2MXht1WntrrK 16020512 (Pubitemid 41565925)
14. C. Hershko A.M. Konijn H.P. Nick W. Breuer Z.I. Cabantchik G. Link 2001 ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture Blood 97 1115 1122 10.1182/blood.V97.4.1115 1:CAS:528:DC%2BD3MXht1Gis78%3D 11159545 (Pubitemid 32154301)
15. H. Nick A. Wong P. Acklin 2002 ICL670A: preclinical profile Adv Exp Med Biol 509 185 203 1:CAS:528:DC%2BD3sXit1Ggurg%3D 12572995
16. A. Taher A. El-Beshlawy M.S. Elalfy 2009 Efficacy and safety of Deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study Eur J Haematol 82 458 465 10.1111/j.1600-0609.2009.01228.x 1:CAS:528:DC%2BD1MXmtVyls7g%3D 19187278
17. J.C. Wood M. Otto-Duessel I. Gonzalez 2006 Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil Transl Res 148 272 280 10.1016/j.trsl.2006.05.005 1:CAS:528:DC%2BD28XhtFems7jP 17145573 (Pubitemid 44634299)
18. E.J. Neufeld 2006 Oral chelators Deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions Blood 107 3436 3441 10.1182/blood-2006-02-002394 1:CAS:528:DC%2BD28Xkt1Git7w%3D 16627763
19. Pathare A, Taher A, Daar S. Deferasirox (Exjade(R)) significantly improves cardiac T2*in heavily iron-overloaded patients with β-thalassemia major. Ann Hematol 2009 Oct 2. [Epub ahead of print]
20. J.L. Stumpf 2007 Deferasirox Am J Health Syst Pharm 64 606 616 10.2146/ajhp060405 1:CAS:528:DC%2BD2sXktFOhsbg%3D 17353569 (Pubitemid 46481861)
21. M.D. Cappellini 2008 Long-term efficacy and safety of Deferasirox Blood Rev 22 S35 S41 10.1016/S0268-960X(08)70007-9 1:CAS:528:DC%2BD1MXhsFShsrw%3D 19059055
22. E. Nisbet-Brown N.F. Olivieri P.J. Giardina 2003 Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 361 1597 1602 10.1016/S0140-6736(03)13309-0 1:CAS:528:DC%2BD3sXjs1Wltbg%3D 12747879 (Pubitemid 36578996)
23. A. Piga R. Galanello G.L. Forni 2006 Randomized phase II trial of Deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to Deferoxamine in Thalassemia patients with transfusional iron overload Haematologica 91 873 880 1:CAS:528:DC%2BD28XnslSnu7c%3D 16818273
24. E. Vichinsky O. Onyekwere J. Porter 2007 Deferasirox in Sickle Cell Investigators. A randomised comparison of Deferasirox versus Deferoxamine for the treatment of transfusional iron overload in sickle cell disease Br J Haematol 136 501 508 10.1111/j.1365-2141.2006.06455.x 1:CAS:528: DC%2BD2sXislShtLY%3D 17233848 (Pubitemid 46046309)
25. J. Porter R. Galanello G. Saglio 2008 Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to Deferasirox (ICL670): a 1-yr prospective study Eur J Haematol 80 168 176 1:CAS:528:DC%2BD1cXivFahtr8%3D 18028431
26. E. Jabbour G. Garcia-Manero A. Taher H.M. Kantarjian 2009 Managing iron overload in patients with myelodysplastic syndromes with oral Deferasirox therapy Oncologist 14 489 496 10.1634/theoncologist.2008-0154 1:CAS:528:DC%2BD1MXnvVOlsbw%3D 19365094
27. M.D. Cappellini A. Taher 2008 Long-term experience with Deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload Expert Opin Pharmacother 9 2391 2402 10.1517/14656566.9.13.2391 1:CAS:528:DC%2BD1cXpvFygurs%3D 18710363
28. L.P. Yang S.J. Keam G.M. Keating 2007 Deferasirox: a review of its use in the management of transfusional chronic iron overload Drugs 67 2211 2230 10.2165/00003495-200767150-00007 1:CAS:528:DC%2BD2sXhsVWkt7fM 17927285
29. M.B. Agarwal 2006 Exjade (ICL 670): A new oral iron chelator J Assoc Physicians India 54 214 217 1:STN:280:DC%2BD28zosVWltw%3D%3D 16800349
30. M.D. Cappellini P. Pattoneri 2009 Oral iron chelators Annu Rev Med 60 25 38 10.1146/annurev.med.60.041807.123243 1:CAS:528:DC%2BD1MXitlyntrY%3D 19630568
31. A. Taher M.D. Cappellini E. Vichinsky 2009 Efficacy and safety of Deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload Br J Haematol 147 752 759 10.1111/j.1365-2141.2009. 07908.x 1:CAS:528:DC%2BD1MXhs1SjtL%2FF 19764988
32. Agarwal MB, Rathi SS, Agarwal UM et al. High-dose (>30 mg/k/d) Deferasirox (Asunra, Desirox) therapy is effective and safe in heavily iron loaded patients - An Indian study. Presented at The Annual Conference of Mumbai Haematology Group, Mumbai, March 2009
33. Exjade. Prescribing Information. April 2009
34. A. Taher M.D. Cappellini 2009 Update on the use of Deferasirox in the management of iron overload Ther Clin Risk Manag 5 857 868 1:CAS:528: DC%2BD1MXhsVKlt7nF 19898650